Intuitive Surgical, a key player in the medical technology sector, has demonstrated resilience despite a recent downturn in its stock performance. While the company's shares have seen a significant reduction from their peak in early 2025, and its price-to-earnings ratio remains elevated, its historical ability to recover from such dips suggests a promising outlook for aggressive investors. This period of intense competition from new market entrants like Medtronic and Johnson & Johnson presents a unique challenge, yet Intuitive Surgical's foundational strengths may offer it a competitive edge.
Intuitive Surgical pioneered the surgical robotics field with its da Vinci system, effectively establishing this specialized niche. Initially, the primary hurdle was the adoption of this novel technology by healthcare providers. Today, surgical robotics is a well-established and widely accepted method for performing less invasive procedures with enhanced patient outcomes. However, the market landscape is shifting as major players like Medtronic and Johnson & Johnson enter the fray. Medtronic secured U.S. approval for its Hugo surgical robotic system in late 2025, followed by Johnson & Johnson's OTTAVA system in mid-2026. Both are formidable competitors with extensive industry networks, posing a significant challenge to Intuitive Surgical's market dominance.
Despite the emergence of new rivals, the immediate impact on Intuitive Surgical's da Vinci system sales is likely to be limited. Surgical robotic systems typically receive approvals for specific types of procedures, meaning competition is initially constrained to particular specialties until broader clearances are obtained. For instance, Intuitive Surgical reported a notable increase in system sales during the second quarter of 2026, selling 468 units compared to 395 in the same period of 2025.
The true strength of Intuitive Surgical lies not merely in the sale of its da Vinci robots, which account for approximately 25% of its total revenue, but in its robust after-sales services and accessories business. The remaining 75% of revenue is generated from services (about 15%) and the sale of instruments and accessories (roughly 60%). This annuity-like revenue model ensures a steady cash flow that grows in tandem with the increasing number and utilization of da Vinci systems globally. With over 11,710 da Vinci systems in operation worldwide, marking a 12% year-over-year increase, and a 16% rise in the number of surgeries performed, the demand for robotic-assisted procedures is evident. This substantial installed base and recurring revenue stream provide Intuitive Surgical with a strong financial foundation, enabling it to effectively contend with diversified healthcare giants entering the surgical robotics market.
Ultimately, the vast healthcare industry can accommodate multiple surgical robotic systems. Intuitive Surgical's established market position and predictable income streams give it a substantial head start. While the stock may be best suited for investors with a higher risk tolerance, its current price-to-earnings ratio of 42x is considerably lower than its five-year average of 68x, suggesting that, from a historical perspective, the company's shares are currently undervalued.
